Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | KHK | P50053 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7170745 | 0.80 | HTR2C (0.42) | HTR2CHTR2BDAOIDO1KHK | |
| SCHEMBL7404347 | 0.80 | SIGMAR1 (0.50) | HTR2CHTR2BTAAR1HTR6SIGMAR1 | |
| SCHEMBL9763617 | 0.80 | DAO (0.46) | HTR2CHTR2BDAOPOLBMEN1 | |
| Hydrochloric Acid SCHEMBL1574641 | 0.78 | HTR2C (0.52) | HTR2CHTR2BTAAR1HTR6SIGMAR1 | |
| SCHEMBL21494727 | 0.74 | DAO (0.45) | HTR2CHTR2BDAOPOLBMEN1 | |
| SCHEMBL30513714 | 0.74 | DAO (0.45) | HTR2CHTR2BDAOPOLBMEN1 | |
| SCHEMBL7065679 | 0.72 | CHRM3 (0.40) | HTR2CHTR2BSIGMAR1 | |
| SCHEMBL29459538 | 0.71 | TAAR1 (0.60) | DAOTAAR1IDO1HRH3 | |
| SCHEMBL1263547 | 0.71 | TAAR1 (0.60) | DAOTAAR1IDO1HRH3 | |
| SCHEMBL30000562 | 0.71 | TAAR1 (0.60) | DAOTAAR1IDO1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662189-B2 | PDE4 inhibitor | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2020-05-26 | — | — | US | disclosed |
| US-20190177318-A1 | PDE4 INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177318-A1 | PDE4 INHIBITOR | PDE4A, PDE12, PDE4B | HTR2C 3205/4885HTR2B 2437/4885DAO 864/4885 |
| US-10662189-B2 | PDE4 inhibitor | PDE4A, PDE12, PDE4B | HTR2C 3205/4885HTR2B 2437/4885DAO 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.